Jennifer Venkatesh
Family · Houston, TXNPI 1538862263
Payments from drug & device makers
Across 81 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$223
- Boehringer Ingelheim$188
- Amgen$173
- Merck$118
- Otsuka America Pharmaceutical, Inc.$94
- Lexicon Pharmaceuticals, Inc.$86
- plus $841 from 22 others
What the payments were for
- Food & beverage$1,723100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,723 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 354 | $313,650 |
| EntrestoSacubitril/Valsartan | 79 | $97,264 |
| XareltoRivaroxaban | 52 | $57,069 |
| BrilintaTicagrelor | 43 | $38,742 |
| JardianceEmpagliflozin | 18 | $18,800 |
| Repatha SureclickEvolocumab | 16 | $15,841 |
| Atorvastatin Calcium | 557 | $6,671 |
| ClopidogrelClopidogrel Bisulfate | 399 | $5,209 |
| Metoprolol Succinate | 287 | $4,780 |
| Carvedilol | 359 | $3,892 |
| Losartan Potassium | 378 | $3,884 |
| Ranolazine ErRanolazine | 32 | $3,862 |
| Metoprolol Tartrate | 466 | $2,966 |
| Olmesartan Medoxomil | 133 | $2,735 |
| Nebivolol Hcl | 43 | $2,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $61 | $313,650354 claims |
| NovartisEntresto | $32 | $97,26479 claims |
| Johnson & JohnsonXarelto | $52 | $57,06952 claims |
| AstraZenecaBrilinta | $81 | $38,74243 claims |
| Boehringer IngelheimJardiance | $188 | $18,80018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.